China’s WuXi AppTec has acquired US clinical research services company Pharmapace, boosting its biometrics capabilities in Europe and the US. Financial details were not disclosed.

Located in San Diego, California, Pharmapace provides biometrics services for all clinical trial phases, including clinical and statistical programming, data management, biostatistics, clinical data integration and medical writing for customers in Europe, North America and Asia.

Pharmapace will become a wholly owned subsidiary of WuXi Clinical, WuXi AppTec’s clinical contract research organization arm, and will continue to focus on growing its core biometrics competences as well as integrating with the Chinese company’s other clinical development services.

Edward Hu, co-CEO of WuXi AppTec, said the acquisition further enhances WuXi Clinical's drug development expertise and biometrics capabilities and lays the foundation for the creation of an efficient and cost effective integrated global biometrics service platform that  will shorten time-to-market of new drugs and achieve the dream that “every drug can be made and every disease can be treated.”

WuXi AppTec added that by integrating both Pharmapace and WuXi Clinical China’s biometrics teams, it will be able to provide services around the clock to customers worldwide.